2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
暂无分享,去创建一个
James E. Tcheng | Christopher J. White | Norman L. Stockbridge | Akshay S. Desai | Steven E. Nissen | Steven R. Steinhubl | David A. Morrow | Kenneth W. Mahaffey | Laura Mauri | Paul Burton | Robert J. Temple | Scott D. Solomon | Christopher M. O’Connor | Michael R. Jaff | Billy Dunn | Roxana Mehran | John J.V. McMurray | M. Landray | S. Solomon | M. Pfeffer | C. O'connor | A. Desai | S. Steinhubl | J. McMurray | B. Dunn | M. Domanski | K. Mahaffey | N. Stockbridge | J. Marler | B. Chaitman | D. Morrow | A. Farb | L. Mauri | A. Lincoff | R. Mehran | S. Nissen | A. Lansky | R. Temple | J. Tcheng | M. Jaff | C. Gibson | D. Cutlip | S. Wiviott | K. Rosenfield | C. White | H. M. Hung | C. Sila | Bernard R. Chaitman | Andrew Farb | Stephen D. Wiviott | Marc A. Pfeffer | C. Michael Gibson | J. Teerlink | K. Hicks | S. Targum | Hylton V. Joffe | E. Lewis | S. Brooks | P. Burton | M. T. Hai | Eldrin F. Lewis | John R. Marler | Alexandra J. Lansky | John R. Teerlink | Martin J. Landray | Michael J. Domanski | Karen A. Hicks | Shari L. Targum | Cathy A. Sila | Mary T. Thanh Hai | Donald E. Cutlip | A. Michael Lincoff | Steven S. Brooks | Kenneth Rosenfield | H.M. James Hung | A. Lincoff | C. White | C. M. Gibson | Michael R. Jaff | Christopher J. White | Marc A. Pfeffer | Scott D Solomon | Akshay S. Desai | David Morrow | Alexandra J. Lansky | Karen A. Hicks | Steven E. Nissen | John R. Marler | Cathy Sila | Mary T. Thanh Hai | C. Michael Gibson | Michael J. Domanski | J. McMurray | Christopher M. O’Connor | H. Hung | Norman L. Stockbridge | Robert J. Temple | David A Morrow | Scott D. Solomon
[1] W. Kannel,et al. The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.
[2] Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. , 1979, Circulation.
[3] J. Karnegis,et al. Development and evolution of electrocardiographic Minnesota Q-QS codes in patients with acute myocardial infarction. , 1985, American heart journal.
[4] J. Slattery,et al. Interobserver agreement for the assessment of handicap in stroke patients. , 1989, Stroke.
[5] Robert A. Zimmerman,et al. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. , 1990, Stroke.
[6] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[7] R. Califf,et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study , 2001, Current controlled trials in cardiovascular medicine.
[8] J. Mohr,et al. Transient ischemic attack--proposal for a new definition. , 2002, The New England journal of medicine.
[9] P. Wolf,et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.
[10] Karl Swedberg,et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.
[11] J. Alpert,et al. Universal definition of myocardial infarction. , 2007, European heart journal.
[12] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[13] C. Granger,et al. Do we need to adjudicate major clinical events? , 2008, Clinical trials.
[14] Regina M. Hardison,et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction , 2009, Circulation.
[15] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[16] M. Laakso,et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. , 2010, European heart journal.
[17] P. Toth. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study , 2010 .
[18] S. Blankenberg,et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. , 2011, JAMA.
[19] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[20] Mary G. George,et al. An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[21] A. Sinha. Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). , 2013 .
[22] E. Braunwald,et al. Unstable Angina: Is It Time for a Requiem? , 2013, Circulation.
[23] R. Rosenfeld. Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[24] S. Solomon,et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT‐CRT , 2014, European journal of heart failure.
[25] Robert H Christenson,et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. , 2014, Journal of the American College of Cardiology.
[26] M. Mack,et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI) , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[27] B. Lindahl,et al. Implications of Introducing High-Sensitivity Cardiac Troponin T Into Clinical Practice: Data From the SWEDEHEART Registry. , 2015, Journal of the American College of Cardiology.
[28] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[29] Mark D. Huffman,et al. Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.
[30] S. Solomon,et al. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.
[31] Jeffrey N. Browndyke,et al. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative , 2018, European heart journal.